Top

Published in:

01-11-2010 | Original Article

Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells

Authors: Hao Chen, Liang Shi, Xiaoyang Yang, Shihui Li, Xiaoling Guo, Ling Pan

Published in: International Journal of Hematology | Issue 4/2010

Abstract

Multiple myeloma (MM) remains an incurable plasma cell disorder to date; therefore, new biologically target-based therapies are in urgent demand. Our previous studies showed that the antimalarial artesunate (ART) possessed anti-myeloma effect by inhibiting proliferation and inducing apoptosis of myeloma cells. The present study evaluated the effect of ART on human myeloma cell-induced angiogenesis and elucidated its mechanism. The human umbilical vein endothelial cells (HUVECs) migration test, aortic sprouting in fibrin gel in vitro and chicken chorioallantoic membrane (CAM) neovascularization in vivo model were used to examine the effect of ART on angiogenesis induced by human myeloma cells. The results showed that ART could inhibit HUVECs migration, even at a lower concentration (3 μmol/l, P < 0.01, compared with the result of control group), and suppress efficiently the angiogenic ability of myeloma RPMI8226 cells in a dose-dependent pattern (3–12 μmol/l, P < 0.05). The levels of VEGF and Ang-1 in the conditioned medium (CM) were quantified by enzyme-linked immunosorbent assay (ELISA). The results confirmed that 3 μmol/l ART could significantly decrease VEGF and Ang-1 secretion by RPMI8226 cells (P < 0.05), which correlated well with the reduction of angiogenesis induced by myeloma RPMI8226 cells. The present study also showed that ART downregulated the expression of VEGF and Ang-1 in RPMI8226 cells and reduced the activation of extracellular signal-regulated kinase 1 (ERK1) as well. Therefore, ART can block ERK1/2 activation, downregulate VEGF and Ang-1 expression and inhibit angiogenesis induced by human multiple myeloma RPMI8226 cells. Combined with our previous published data, results from the present study indicate that ART possesses potential anti-myeloma effect.

Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324–39.CrossRefPubMed

Sezer O, Niemoller K, Eucker J, Jakob C, Kaufmann O, Zavrski I, et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol. 2000;79:574–7.CrossRefPubMed

Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20:193–9.CrossRefPubMed

Rajkumar SV, Leong T, Roche PC, Fonseca R, Dispenzieri A, Lacy MQ, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res. 2000;6:3111–6.PubMed

Thurston G. Complementary actions of VEGF and angiopoietin-1 on blood vessel growth and leakage. J Anat. 2002;200:575–80.CrossRefPubMed

Bellamy WT. Expression of vascular endothelial growth factor and its receptors in multiple myeloma and other hematopoietic malignancies. Semin Oncol. 2001;28:551–9.CrossRefPubMed

Markovic O, Marisavljevic D, Cemerikic V, Vidovic A, Perunicic M, Todorovic M, et al. Expression of VEGF and microvessel density in patients with multiple myeloma: clinical and prognostic significance. Med Oncol. 2008;25:451–7.CrossRefPubMed

Podar K, Anderson KC. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle. 2007;6:538–42.PubMed

Liu XH, Bai CG, Yuan Y, Gong DJ, Huang SD. Angiopoietin-1 targeted RNA interference suppresses angiogenesis and tumor growth of esophageal cancer. World J Gastroenterol. 2008;14:1575–81.CrossRefPubMed

10.

Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH. Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol. 2004;165:1557–70.PubMed

11.

Shim WS, Teh M, Bapna A, Kim I, Koh GY, Mack PO, et al. Angiopoietin-1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res. 2002;279:299–309.CrossRefPubMed

12.

Giuliani N, Lunghi P, Morandi F, Colla S, Bonomini S, Hojden M, et al. Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis. Leukemia. 2004;18:628–35.CrossRefPubMed

13.

Klayman DL. Qinghaosu (artemisinin): the antimalarial drug from China. Science. 1985;228:1049–55.CrossRefPubMed

14.

Woerdenbag HJ, Pras N, van Uden W, Wallart TE, Beekman AC, Lugt CB. Progress in the research of artemisinin-related antimalarials: an update. Pharm World Sci. 1994;16:169–80.CrossRefPubMed

15.

Price RN. Artemisinin drugs: novel antimalarial agents. Expert Opin Investig Drugs. 2000;9:1815–27.CrossRefPubMed

16.

Hien TT, Phu NH, Mai NT, Chau TT, Trang TT, Loc PP, et al. An open randomized comparison of intravenous and intramuscular artesunate in severe falciparum malaria. Trans R Soc Trop Med Hyg. 1992;86:584–5.CrossRefPubMed

17.

Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JG, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis. 2008;47:804–11.CrossRefPubMed

18.

Dhingra V, Vishweshwar Rao K, Lakshmi Narasu M. Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci. 2000;66:279–300.CrossRefPubMed

19.

He RR, Zhou HJ. Progress in research on the anti-tumor effect of artesunate. Chin J Integr Med. 2008;14:312–6.CrossRefPubMed

20.

Efferth T, Briehl MM, Tome ME. Role of antioxidant genes for the activity of artesunate against tumor cells. Int J Oncol. 2003;23:1231–5.PubMed

21.

Zhou HJ, Wang WQ, Wu GD, Lee J, Li A. Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemia K562 cells. Vascul Pharmacol. 2007;47:131–8.CrossRefPubMed

22.

Dell’Eva R, Pfeffer U, Vene R, Anfosso L, Forlani A, Albini A, et al. Inhibition of angiogenesis in vivo and growth of Kaposi’s sarcoma xenograft tumors by the anti-malarial artesunate. Biochem Pharmacol. 2004;68:2359–66.CrossRefPubMed

23.

Li SH, Xue F, Cheng ZY, Yang XY, Wang SY, Pan L, et al. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int J Hematol. 2009;90:513–21.CrossRefPubMed

24.

Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood. 2001;97:3919–24.CrossRefPubMed

25.

Nicosia RF, Ottinetti A. Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Investig. 1990;63:115–22.PubMed

26.

Ribatti D, De Falco G, Nico B, Ria R, Crivellato E, Vacca A. In vivo time-course of the angiogenic response induced by multiple myeloma plasma cells in the chick embryo chorioallantoic membrane. J Anat. 2003;203:323–8.CrossRefPubMed

27.

Klagsbrun M, Moses MA. Molecular angiogenesis. Chem Biol. 1999;6:217–24.CrossRef

28.

Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001;18:767–73.PubMed

29.

Chen HH, Zhou HJ, Wu GD, Luo XE. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 2004;71:1–9.CrossRefPubMed

30.

Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–8.CrossRefPubMed

31.

Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene. 1999;18:5356–62.CrossRefPubMed

32.

Suri C, McClain J, Thurston G, McDonald DM, Zhou H, Oldmixon EH, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282:468–71.CrossRefPubMed

33.

Uneda S, Matsuno F, Sonoki T, Tniguchi L, Kawano F, Hata H. Expressions of vascular endothelial growth factor and angiopoietin-2 in myeloma cells. Haematologica. 2003;88:113–5.PubMed

34.

Giuliani N, Colla S, Morandi F, Rizzoli V. Angiopoietin-1 and myeloma-induced angiogenesis. Leuk Lymphoma. 2005;46:29–33.CrossRefPubMed

35.

Fragoso R, Elias AP, Dias S. Autocrine VEGF loops, signaling pathways, and acute leukemia regulation. Leuk Lymphoma. 2007;48:481–8.CrossRefPubMed

36.

Chinoy MR, Graybill MM, Miller SA, Lang CM, Kauffman GL. Angiopoietin-1 and VEGF in vascular development and angiogenesis in hypoplastic lungs. Am J Physiol Lung Cell Mol Physiol. 2002;283:L60–6.PubMed

37.

Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004;104:2886–92.CrossRefPubMed

Title: Artesunate inhibiting angiogenesis induced by human myeloma RPMI8226 cells
Authors: Hao Chen
Liang Shi
Xiaoyang Yang
Shihui Li
Xiaoling Guo
Ling Pan
Publication date: 01-11-2010
Publisher: Springer Japan
Published in: International Journal of Hematology / Issue 4/2010
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI: https://doi.org/10.1007/s12185-010-0697-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib

Successful salvage treatment of blastic natural killer cell lymphoma with methotrexate

AA amyloidosis associated with macroglobulinemia

Aggressive sporadic histiocytic sarcoma with immunoglobulin heavy chain gene rearrangement and t(14;18)

Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience

Keynote webinar | Spotlight on antibody–drug conjugates in cancer